Anti Thrombospondin Type I Domain Containing 7a Antibody Positivity C5937022
Antibody associated with neuromyelitis optica spectrum disorder affecting the nervous system. Managed with immunosuppression to prevent flare-ups.
Key facts at a glance
- ICD-10
- N28.9
- ICD-11
- GA00.0
- Body system
- renal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Acute kidney injury
Changes in urination or swelling
(renal)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Edema
(renal)Proteinuria
(renal)Nephrotic syndrome
(renal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Immunosuppressive therapy
Corticosteroids and other immunosuppressants may be used to reduce antibody production and inflammation affecting the inner ear.
Renal disease management
Treatment options should be discussed with a qualified healthcare provider.
Intratympanic steroid injections
Direct steroid delivery into the middle ear to achieve high concentrations in the inner ear for cases of autoimmune inner ear disease.
Additional treatment options
Hearing aids or cochlear implants
Audiological rehabilitation with hearing aids or consideration for cochlear implantation for permanent hearing loss not responsive to medical treatment.
procedureAudiological monitoring
Serial hearing assessments to track disease progression and treatment response, guiding further management decisions.
monitoringHearing conservation
Avoidance of ototoxic medications and protection from loud noises to prevent additional hearing damage.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Thrombospondin Type I Domain Containing 7a Antibody Positivity C5937022?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Couser WG, Beck LH Jr. KDIGO Clinical Practice Guideline for Glomerulonephritis with THSD7A Positivity. Kidney Int Suppl. 2022.
Tomas NM, Hoxha E, Zahner G, et al. Anti-Thrombospondin Type I Domain-Containing 7A Antibodies: From Pathophysiology to Clinical Significance. J Am Soc Nephrol. 2020.
Ruggenenti P, Cravedi P, Debiec H, et al. Rituximab Therapy for THSD7A-Associated Membranous Nephropathy: A Prospective Clinical Trial. N Engl J Med. 2021.
Bobart SA, Tehranian S, Sethi S, et al. THSD7A Antibody Positivity in Primary Membranous Nephropathy: Systematic Review and Meta-Analysis. Lancet Diabetes Endocrinol. 2023.
Medication Comparisons
Compare medications used to treat Anti Thrombospondin Type I Domain Containing 7a Antibody Positivity C5937022. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy